Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

West Pharmaceutical Services Inc / Equity Bottom-Up

West Pharmaceutical Services Inc (WST US)

<ul><li>West Pharmaceutical Services reported a robust start to fiscal year 2026, with first-quarter revenues reaching $845 million, marking a 21% increase on a reported basis and 15% on an organic basis, surpassing company expectations.</li><li>Adjusted operating margins expanded by 350 basis points to 21.4%, and adjusted earnings per share rose 47% year-over-year to $2.13.</li><li>These results led the company to raise its full-year 2026 outlook, now projecting organic revenue growth of 7% to 9% (up from previous guidance of 5% to 7%) and adjusted EPS of $8.40 to $8.75, representing a 15% to 20% increase.</li></ul>

West Pharmaceutical Services reported a robust start to fiscal year 2026, with first-quarter revenues reaching $845 million, marking a 21% increase on a reported basis and 15% on an organic basis, surpassing company expectations.Adjusted operating margins expanded by 350 basis points to 21.4%, and adjusted earnings per share rose 47% year-over-year to $2.13.These results led the company to raise its full-year 2026 outlook, now projecting organic revenue growth of 7% to 9% (up from previous guidance of 5% to 7%) and adjusted EPS of $8.40 to $8.75, representing a 15% to 20% increase.

West Pharmaceutical Services: Is Riding The Biologics Boom — But How Sustainable Is This High-Growth Wave?

<ul><li>West Pharmaceutical Services reported its financial results for the fourth quarter and full year of 2025, showcasing a period of growth and strategic execution.</li><li>The company achieved significant milestones, including surpassing $3 billion in net sales with organic growth of over 4% year-over-year, expanding operating margins, and achieving an 8% growth in adjusted earnings per share (EPS).</li><li>The fourth quarter revenues were $805 million, a 7.5% increase year-over-year, exceeding expectations along with a 12% rise in adjusted EPS to $2.04.</li></ul>

West Pharmaceutical Services reported its financial results for the fourth quarter and full year of 2025, showcasing a period of growth and strategic execution.The company achieved significant milestones, including surpassing $3 billion in net sales with organic growth of over 4% year-over-year, expanding operating margins, and achieving an 8% growth in adjusted earnings per share (EPS).The fourth quarter revenues were $805 million, a 7.5% increase year-over-year, exceeding expectations along with a 12% rise in adjusted EPS to $2.04.

West Pharmaceutical Services: Demand Is Outrunning Supply—Can Capacity Investments Close the Gap?

<ul><li>West Pharmaceutical Services delivered solid third-quarter results for 2025, showing noteworthy improvements across key metrics.</li><li>The company reported revenues of $805 million, marking a 5% organic increase, which exceeded their internal expectations.</li><li>The adjusted operating margin was 21.1%, while the adjusted EPS increased by 6% to $1.96 compared to the previous year.</li></ul>

West Pharmaceutical Services delivered solid third-quarter results for 2025, showing noteworthy improvements across key metrics.The company reported revenues of $805 million, marking a 5% organic increase, which exceeded their internal expectations.The adjusted operating margin was 21.1%, while the adjusted EPS increased by 6% to $1.96 compared to the previous year.

West Pharmaceutical Services: High-Value Product Components Expansion As A Significant Needle Mover In The Company's Future Performance!

<ul><li>West Pharmaceutical Services Inc.'s second quarter (Q2) of 2025 revealed a solid performance above expectations with net sales increasing by 9.2%, and 6.8% on an organic basis.</li><li>Driven primarily by the growth in high-value product (HVP) components, especially through strong GLP-1 elastomer uptake, the results underscore West's position in the injectable solutions market.</li><li>This position is strengthened by a strategic focus on areas like biologics and biosimilars.</li></ul>

West Pharmaceutical Services Inc.'s second quarter (Q2) of 2025 revealed a solid performance above expectations with net sales increasing by 9.2%, and 6.8% on an organic basis.Driven primarily by the growth in high-value product (HVP) components, especially through strong GLP-1 elastomer uptake, the results underscore West's position in the injectable solutions market.This position is strengthened by a strategic focus on areas like biologics and biosimilars.

West Pharmaceutical: High-Value Product (HVP) Components Growth & Other Factors Powering Our Optimism!

Pharma/ Biotechnology Investments Specialist, Vasuda Capital Management

Dr. Bhavneesh Sharma, MD, MBA

Pharma/ Biotechnology Investments Specialist

Vasuda Capital Management

Thematic (Sector/Industry)

<p><a href="https://www.smartkarma.com/entities/17686" target="_blank" data-smartkarma-citation="entities:17686:1">Ziopharm Oncology Inc (ZIOP US)</a> announced impressive survival data for its immune-boosting therapy AD-RTS-hIL-12 + veledimex in recurrent pediatric malignant glioma (a form of deadly brain cancer). Median overall survival almost doubled to 12.8 months vs. currently available therapies. In addition, any toxic effects were reversible on stopping veledimex (which thus acts as a control switch for the therapy). Griffin Securities reissued buy rating with price target of US$21 after the data was…</p>

Ziopharm Oncology Inc (ZIOP US) announced impressive survival data for its immune-boosting therapy AD-RTS-hIL-12 + veledimex in recurrent pediatric malignant glioma (a form of deadly brain cancer). Median overall survival almost doubled to 12.8 months vs. currently available therapies. In addition, any toxic effects were reversible on stopping veledimex (which thus acts as a control switch for the therapy). Griffin Securities reissued buy rating with price target of US$21 after the data was…

Actionable Ideas in the Biotechnology and Pharmaceutical Sectors (Incl. Insider Buying): November 28

United States

West Pharmaceutical Services, Inc. applies value-added services to the process of bringing new drug therapies and healthcare products to global markets. The Company's technologies include the design and manufacture of packaging components, research and development of drug delivery systems, and contract laboratory services and other services.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

West Pharmaceutical Services Inc (WST US)

West Pharmaceutical Services: Is Riding The Biologics Boom — But How Sustainable Is This High-Growth Wave?

West Pharmaceutical Services reported a robust start to fiscal year 2026, with first-quarter revenues reaching $845 million, marking a 21%...

Baptista Research

West Pharmaceutical Services: Demand Is Outrunning Supply—Can Capacity Investments Close the Gap?

West Pharmaceutical Services reported its financial results for the fourth quarter and full year of 2025, showcasing a period of growth and...

Baptista Research

West Pharmaceutical Services: High-Value Product Components Expansion As A Significant Needle Mover In The Company's Future Performance!

West Pharmaceutical Services delivered solid third-quarter results for 2025, showing noteworthy improvements across key metrics. The company...

Baptista Research

West Pharmaceutical: High-Value Product (HVP) Components Growth & Other Factors Powering Our Optimism!

West Pharmaceutical Services Inc.'s second quarter (Q2) of 2025 revealed a solid performance above expectations with net sales increasing by 9.2%,...

Baptista Research

Actionable Ideas in the Biotechnology and Pharmaceutical Sectors (Incl. Insider Buying): November 28

Ziopharm Oncology Inc (ZIOP US) announced impressive survival data for its immune-boosting therapy AD-RTS-hIL-12 + veledimex in recurrent pediatric...

Dr. Bhavneesh Sharma, MD, MBA

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)